Discovery Laboratories has announce the launch of its Afectair airway connector for the delivery of aerosolized medications to infants in neonatal or pediatric intensive care units. The disposable device enables delivery of aerosolized drugs to patients on ventilatory support at the patient interface and was initially developed in conjunction with the company’s Aerosurf lucinactant for inhalation development project.
According to Discovery Labs, the first phase of the launch will involve approximately ten percent of the target facilities, and the company will wait until the second quarter of 2013 for a wide launch. The company also hopes that Afectair will get European Conformity (CE) marking for infants in 2013.
The company estimates that about 355,000 US pediatric patients on ventilatory support could receive aerosolized medications annually.
Read the Discovery Labs press release.
